Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | LYN | P07948 | 2/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12962037 | 0.80 | PARP1 (0.46) | PARP1ALDH1A1CHEK1PIM1RPS6KA3 | |
| SCHEMBL15760947 | 0.79 | PARP1 (0.38) | PARP1XDHSYKCHEK1PIM1 | |
| SCHEMBL1059335 | 0.79 | PARP1 (0.44) | PARP1ALDH1A1SYKPIM1KCNH2 | |
| SCHEMBL1059900 | 0.79 | PARP1 (0.49) | PARP1ALDH1A1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1083326 | 0.79 | XDH (0.44) | PARP1XDHSYKKCNH2JAK2 | |
| SCHEMBL1057202 | 0.76 | SYK (0.45) | SYKJAK2 | |
| SCHEMBL14641821 | 0.76 | PARP1 (0.43) | PARP1ALDH1A1CHEK1PIM1RPS6KA3 | |
| SCHEMBL1058535 | 0.74 | PARP1 (0.49) | PARP1JAK2ZAP70 | |
| SCHEMBL1057076 | 0.74 | JAK1 (0.41) | PARP1SYKJAK2 | |
| SCHEMBL15760946 | 0.74 | CHEK1 (0.43) | CHEK1RPS6KA3JAK2ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | PARP1 271/4885ALDH1A1 161/4885XDH 1213/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | PARP1 260/4885ALDH1A1 140/4885XDH 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.